NCT05007509View on ClinicalTrials.gov

Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2022

Conditions
Covid19SARS CoV 2 Infection
Interventions
BIOLOGICAL

COVID-19 vaccine HIPRA 10

One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg

BIOLOGICAL

COVID-19 vaccine HIPRA 20

One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg

BIOLOGICAL

COVID-19 vaccine HIPRA 40

One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg

BIOLOGICAL

Commercial COVID-19 vaccine

One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine

Trial Locations (2)

17007

Hospital Universitari Dr. Josep Trueta, Girona

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Laboratorios Hipra, S.A.

INDUSTRY

NCT05007509 - Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) | Biotech Hunter | Biotech Hunter